{"transactions":[{"id":4274026,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-21","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":3000,"derivative":{"exercise_price":30.63,"expiration_date":"2020-12-14","underlying":"Common Stock","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274025,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":541,"value":54100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":4693,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274024,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":538.3,"value":53830.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":4793,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274023,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":537.5,"value":53750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":4893,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274022,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":400,"price":536.52,"value":214608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents volume-weighted average price of sales of 400 shares of Company stock on June 22, 2017 at prices ranging from $536.15 to $536.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":4993,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274021,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":200,"price":534.51,"value":106902.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $534.16 to $534.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":5393,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274020,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":200,"price":533.48,"value":106696.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $533.17 to $533.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":5593,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274019,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":200,"price":532.27,"value":106454.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents volume-weighted average price of sales of 200 shares of Company stock on June 22, 2017 at prices ranging from $532.18 to $532.35. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":5793,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274018,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":274,"price":531.51,"value":145633.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents volume-weighted average price of sales of 274 shares of Company stock on June 22, 2017 at prices ranging from $531.05 to $531.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":5993,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274017,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":530.66,"value":53066.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6267,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274016,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":529.61,"value":52961.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6367,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274015,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":100,"price":526.02,"value":52602.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6467,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274014,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-22","kind":"sale","acquired":false,"shares":395,"price":525.21,"value":207457.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents volume-weighted average price of sales of 395 shares of Company stock on June 22, 2017 at prices ranging from $525.00 to $525.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 22, 2017 at each separate price."}],"balance_after":6567,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274013,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-21","kind":"tax_withholding","acquired":false,"shares":1961,"price":510.02,"value":1000149.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":6962,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274012,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-21","kind":"tax_withholding","acquired":false,"shares":270,"price":510.02,"value":137705.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":8923,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4274011,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Common Stock","published_at":"2017-06-23T20:10:08.000Z","date":"2017-06-21","kind":"exercise","acquired":true,"shares":4500,"price":30.63,"value":137835.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c)."}],"balance_after":9193,"source":{"system":"sec-edgar","filing":"0001708138-17-000011","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000170813817000011/edgardoc.xml","form_type":"4"}},{"id":4517638,"issuer":{"id":2010,"kind":"organization","name":"REGENERON PHARMACEUTICALS, INC.","symbol":"REGN"},"owners":[{"id":174971,"kind":"person","name":"Aberman Michael S","position":1,"cik":"0001487767","reported_name":"Aberman Michael S","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Strategy Investor Relation"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2016-12-19T21:17:36.000Z","date":"2016-12-16","kind":"grant","acquired":true,"shares":21675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award vests in four equal annual installments, commencing one year after the date of grant."}],"balance_after":21675,"derivative":{"exercise_price":381.92,"expiration_date":"2026-12-16","underlying":"Common Stock","underlying_shares":21675},"source":{"system":"sec-edgar","filing":"0001237899-16-000092","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/872589/000123789916000092/edgardoc.xml","form_type":"4"}}]}